{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 38,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a numbered list format to present key value drivers including clinical status, regulatory pathway, and market opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/32",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.2,
        "x": 0.75,
        "y": 0.00175
      },
      "kind": "image",
      "text": "Beaker with test tubes",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a31e06e1-6bd9-40e3-abca-017a1c27b167",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "1. Nefecon is a proprietary, novel treatment for IgAN intended to be disease modifying\n2. Nefecon targets the presumed origin of the disease – the area of the ileum where the highest concentration of Peyer's patches are located\n3. Nefecon is the most advanced product candidate for IgAN. The only successful randomized, double-blind, placebo-controlled Phase 2b clinical trial carried out in IgAN to date\n4. Ongoing pivotal Phase 3 clinical trial (NefIgArd) using the same primary endpoint as previous successful Phase 2b trial\n5. Regulatory pathway based on FDA and EMA acceptance of accelerated / conditional approval based on proteinuria as surrogate marker for IgAN\n6. Significant unmet medical need in IgAN with no currently approved treatments; total market opportunity of US$9-10bn in the U.S alone.\n7. Additional potential for pipeline development and in-licensing of product candidates targeting orphan diseases",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5db5b18f-53e2-4048-85a5-3f983a90ffd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Investment highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fa20c2a-a840-4423-822b-f71b9db1f21b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "bea667db-e8c2-42f8-ac97-075c570ee28b",
      "evidence": "1. Nefecon is a proprietary, novel treatment for IgAN intended to be disease modifying",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "6d9f4842-8e78-4470-9b77-62ddb25b5816",
      "evidence": "Numbered list of key investment highlights",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 32,
      "from": 31,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "6b785561-4009-41a7-ba36-3b1cce235cfa",
      "evidence": "The document presents the anticipated milestones and the potential for Nefecon to be the first approved treatment for IgAN.",
      "position": 1,
      "objective": "Why is now the right time to invest in Nefecon?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}